15 shown
| # | Company | Score | Growth | Margin | Mkt cap | F |
|---|---|---|---|---|---|---|
| 1 | KRYSKrystal Biotech, Inc. | 100 | 34% | 54% | $11.1B | — |
| 2 | INCYINCYTE CORP | 93 | 21% | 25% | $23.3B | 8 |
| 3 | NBIXNEUROCRINE BIOSCIENCES INC | 86 | 21% | 22% | $17.5B | 6 |
| 4 | MEDPMedpace Holdings, Inc. | 79 | 20% | 17% | $15.9B | — |
| 5 | EXELEXELIXIS, INC. | 71 | 7% | 34% | $14.0B | 6 |
| 6 | AMGNAMGEN INC | 64 | 10% | 21% | $201.9B | 7 |
| 7 | GILDGILEAD SCIENCES, INC. | 57 | 2% | 31% | $163.0B | 8 |
| 8 | IQVIQVIA HOLDINGS INC. | 50 | 6% | 8% | $34.6B | — |
| 9 | BIIBBIOGEN INC. | 43 | 2% | 14% | $31.9B | 5 |
| 10 | TECHBIO-TECHNE Corp | 36 | 5% | 9% | $11.0B | 5 |
| 11 | ICLRICON PLC | 29 | 1% | 3% | $13.3B | — |
| 12 | CRLCHARLES RIVER LABORATORIES INTERNATIONAL, INC. | 21 | -1% | -5% | $11.1B | — |
| 13 | BNTXBioNTech SE | 14 | 4% | -40% | $24.7B | — |
| 14 | MRNAModerna, Inc. | 7 | -40% | -144% | $31.6B | 3 |
| 15 | ARGXARGENX SE | 0 | 254% | -830% | $58.4B | — |
Ranked by percentile of (0.6 × revenue growth + 0.4 × net margin) within the Biotechnology · large-cap cohort (15 companies). Score 0–100. Click a column to re-sort; Best/Worst flip the cohort ranking.